Lee Scott Golden, the EVP & CHIEF MEDICAL OFFICER of $PTCT, sold 897 shares of the company on 04-02-2025 for an estimated $42,114. We received data on the trade from a recent SEC filing. This was a sale of approximately 1.2% of their shares of this class of stock. Following this trade, they now own 75,997 shares of this class of $PTCT stock.
$PTCT Insider Trading Activity
$PTCT insiders have traded $PTCT stock on the open market 69 times in the past 6 months. Of those trades, 0 have been purchases and 69 have been sales.
Here’s a breakdown of recent trading of $PTCT stock by insiders over the last 6 months:
- MARK ELLIOTT BOULDING (EXEC. VP AND CLO) has made 0 purchases and 19 sales selling 193,337 shares for an estimated $10,159,420.
- NEIL GREGORY ALMSTEAD (CHIEF TECHNICAL OPS OFFICER) has made 0 purchases and 14 sales selling 77,535 shares for an estimated $4,009,259.
- JEROME B ZELDIS has made 0 purchases and 5 sales selling 24,000 shares for an estimated $1,235,897.
- CHRISTINE MARIE UTTER (SVP, CHIEF ACCOUNTING OFFICER) has made 0 purchases and 8 sales selling 22,510 shares for an estimated $1,142,121.
- MATTHEW B. KLEIN (CHIEF EXECUTIVE OFFICER) has made 0 purchases and 5 sales selling 20,615 shares for an estimated $968,344.
- ERIC PAUWELS (CHIEF BUSINESS OFFICER) has made 0 purchases and 9 sales selling 17,900 shares for an estimated $945,231.
- STEPHANIE OKEY sold 5,000 shares for an estimated $270,000
- LEE SCOTT GOLDEN (EVP & CHIEF MEDICAL OFFICER) has made 0 purchases and 5 sales selling 4,662 shares for an estimated $220,196.
- PIERRE GRAVIER (CHIEF FINANCIAL OFFICER) has made 0 purchases and 2 sales selling 2,335 shares for an estimated $117,006.
- ALLAN STEVEN JACOBSON sold 1,230 shares for an estimated $63,369
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$PTCT Hedge Fund Activity
We have seen 125 institutional investors add shares of $PTCT stock to their portfolio, and 90 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- TORONTO DOMINION BANK added 3,286,729 shares (+inf%) to their portfolio in Q4 2024, for an estimated $148,362,947
- WELLINGTON MANAGEMENT GROUP LLP removed 3,105,676 shares (-39.3%) from their portfolio in Q4 2024, for an estimated $140,190,214
- DRIEHAUS CAPITAL MANAGEMENT LLC added 1,041,059 shares (+inf%) to their portfolio in Q4 2024, for an estimated $46,993,403
- UBS GROUP AG added 905,980 shares (+548.8%) to their portfolio in Q4 2024, for an estimated $40,895,937
- POINT72 ASSET MANAGEMENT, L.P. added 867,502 shares (+150.6%) to their portfolio in Q4 2024, for an estimated $39,159,040
- ARMISTICE CAPITAL, LLC removed 856,898 shares (-11.8%) from their portfolio in Q4 2024, for an estimated $38,680,375
- JACOBS LEVY EQUITY MANAGEMENT, INC removed 659,778 shares (-44.4%) from their portfolio in Q4 2024, for an estimated $29,782,378
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$PTCT Analyst Ratings
Wall Street analysts have issued reports on $PTCT in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Cantor Fitzgerald issued a "Overweight" rating on 02/03/2025
- RBC Capital issued a "Outperform" rating on 01/07/2025
To track analyst ratings and price targets for $PTCT, check out Quiver Quantitative's $PTCT forecast page.
$PTCT Price Targets
Multiple analysts have issued price targets for $PTCT recently. We have seen 3 analysts offer price targets for $PTCT in the last 6 months, with a median target of $52.0.
Here are some recent targets:
- Brian Abrahams from RBC Capital set a target price of $58.0 on 01/07/2025
- Joel Beatty from Robert W. Baird set a target price of $52.0 on 11/27/2024
- Jeffrey Hung from Morgan Stanley set a target price of $45.0 on 10/11/2024
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
